Nomelcitinib Market Summary

Key Factors Driving Nomelcitinib Growth

1. Progression into Phase III development for plaque psoriasis

Nomelcitinib's advancement into Phase III development for plaque psoriasis is an important potential commercial driver. This progression follows encouraging Phase II results and indicates that the compound has reached a later stage of clinical evaluation in China. Successful Phase III trials could support regulatory submissions and establish a pathway toward commercialization. However, the drug remains investigational, and approval will depend on confirmatory efficacy and safety data.

2. Positive Phase II results in moderate-to-severe plaque psoriasis

In December 2024, InventisBio announced positive Phase II results for D-2570 in patients with moderate-to-severe plaque psoriasis. The study enrolled 161 patients, evaluating oral doses of 18 mg and 27 mg. These findings supported further clinical development and provided an initial clinical basis for assessing its potential in psoriasis. The magnitude and durability of efficacy, safety during longer treatment, and comparison with established oral therapies and biologics will be important determinants of future prescribing and market uptake.

3. Oral once-daily administration and treatment convenience

Nomelcitinib is administered orally once daily in its Phase II psoriasis study, offering a potentially convenient alternative to injectable biologic treatments. Oral administration may appeal to patients who prefer tablets over injections and could simplify long-term disease management. Its commercial competitiveness will nevertheless depend on sustained efficacy, tolerability, dosing convenience, and comparative performance against approved oral TYK2 inhibitors and biologics.

4. Potential expansion into ulcerative colitis

InventisBio initiated a Phase II study of D-2570 in moderate-to-severe active ulcerative colitis, with the first patient dosed in May 2025. TYK2 regulates cytokine pathways, including IL-12 and IL-23 signaling, that contribute to inflammatory responses. If the drug demonstrates meaningful efficacy in ulcerative colitis, this could expand its addressable patient population beyond dermatology. However, efficacy in psoriasis does not establish efficacy in inflammatory bowel disease, and clinical results will be necessary to validate this opportunity.

5. Broader autoimmune-disease development opportunities

Nomelcitinib's mechanism offers opportunities to investigate additional immune-mediated conditions. Development records identify systemic lupus erythematosus, psoriatic arthritis, and non-segmental vitiligo among its clinical development areas. Successful results across multiple indications could diversify its future revenue sources and reduce dependence on psoriasis alone. Each indication will require separate clinical validation, and the number of investigational indications should not be interpreted as evidence that the drug will succeed in all of them.

Nomelcitinib Recent Developments

In July 2025, InventisBio initiated a multi-center, randomized Phase III clinical trial evaluating Nomelcitinib in patients with moderate-to-severe plaque psoriasis. This study follows stellar Phase II results where 75% to 77.5% of patients achieved PASI 90 at 12 weeks, rivaling injectable biologics.

“Nomelcitinib Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Nomelcitinib for potential indication like Plaque psoriasis, Psoriatic arthritis, Systemic lupus erythematosus, Ulcerative colitis, and Vitiligo in the 7MM. A detailed picture of Nomelcitinib’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Nomelcitinib for potential indications. The Nomelcitinib market report provides insights about Nomelcitinib’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Nomelcitinib performance, future market assessments inclusive of the Nomelcitinib market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Nomelcitinib sales forecasts, along with factors driving its market.

Nomelcitinib Drug Summary

Nomelcitinib also known as D-2570, is an investigational, orally administered, small-molecule inhibitor of tyrosine kinase 2 (TYK2) developed by InventisBio for the treatment of autoimmune and inflammatory diseases. It selectively targets the Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling pathway by inhibiting the TYK2 pseudokinase JH2 domain, thereby modulating cytokine-mediated immune responses, particularly signaling associated with interleukin-23 (IL-23), which plays an important role in inflammatory conditions such as plaque psoriasis. By suppressing these pathways, nomelcitinib aims to reduce abnormal immune activation and inflammation while offering the convenience of oral administration compared with injectable biologic therapies. The drug is being investigated across several indications, including moderate-to-severe plaque psoriasis, systemic lupus erythematosus, psoriatic arthritis, ulcerative colitis, and non-segmental vitiligo. Clinical development has advanced to Phase III for plaque psoriasis, following encouraging Phase II results demonstrating improvements in psoriasis severity, while Phase II studies are exploring its potential in additional autoimmune diseases. As of October 2026, nomelcitinib remains an investigational drug and has not received marketing approval from any regulatory authority. The report provides Nomelcitinib’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Nomelcitinib Market Report

The report provides insights into:

• A comprehensive product overview including the Nomelcitinib MoA, description, dosage and administration, research and development activities in potential indication like Plaque psoriasis, Psoriatic arthritis, Systemic lupus erythematosus, Ulcerative colitis, and Vitiligo.
• Elaborated details on Nomelcitinib regulatory milestones and other development activities have been provided in Nomelcitinib market report.
• The report also highlights Nomelcitinib‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Nomelcitinib market report also covers the patents information, generic entry and impact on cost cut.
• The Nomelcitinib market report contains current and forecasted Nomelcitinib sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Nomelcitinib market report also features the SWOT analysis with analyst views for Nomelcitinib in potential indications.

Methodology

The Nomelcitinib market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Nomelcitinib Analytical Perspective by DelveInsight

• In-depth Nomelcitinib Market Assessment

This Nomelcitinib sales market forecast report provides a detailed market assessment of Nomelcitinib for potential indication like Plaque psoriasis, Psoriatic arthritis, Systemic lupus erythematosus, Ulcerative colitis, and Vitiligo in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Nomelcitinib sales data uptil 2034.

• Nomelcitinib Clinical Assessment

The Nomelcitinib market report provides the clinical trials information of Nomelcitinib for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Nomelcitinib Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Nomelcitinib Market Potential & Revenue Forecast

• Projected market size for the Nomelcitinib and its key indications
• Estimated Nomelcitinib sales potential (Nomelcitinib peak sales forecasts)
• Nomelcitinib Pricing strategies and reimbursement landscape

Nomelcitinib Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Nomelcitinib Market positioning compared to existing treatments
• Nomelcitinib Strengths & weaknesses relative to competitors

Nomelcitinib Regulatory & Commercial Milestones

• Nomelcitinib Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Nomelcitinib Clinical Differentiation

• Nomelcitinib Efficacy & safety advantages over existing drugs
• Nomelcitinib Unique selling points

Nomelcitinib Market Report Highlights

• In the coming years, the Nomelcitinib market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Nomelcitinib companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Nomelcitinib’s dominance.
• Other emerging products for Plaque psoriasis, Psoriatic arthritis, Systemic lupus erythematosus, Ulcerative colitis, and Vitiligo are expected to give tough market competition to Nomelcitinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Nomelcitinib in potential indications.
• Analyse Nomelcitinib cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Nomelcitinib sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Nomelcitinib in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Nomelcitinib? How strong is Nomelcitinib’s clinical and commercial performance?
• What is Nomelcitinib’s clinical trial status in each individual indications such as Plaque psoriasis, Psoriatic arthritis, Systemic lupus erythematosus, Ulcerative colitis, and Vitiligo and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Nomelcitinib Manufacturers?
• What are the key designations that have been granted to Nomelcitinib for potential indications? How are they going to impact Nomelcitinib’s penetration in various geographies?
• What is the current and forecasted Nomelcitinib market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Nomelcitinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Nomelcitinib for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Nomelcitinib? What is the duration of therapy and what are the geographical variations in cost per patient?